Skip to content Skip to footer
Subscribe Now
Disease of the Month: Dengue Disease
INSIGHTS+

Disease of the Month: Dengue Diseas

In India, 16 May is observed as National Dengue Day. Dengue is a mosquito-borne viral disease transmitted by female mosquitoes of the Aedes aegypti species infected by any of the four dengue virus serotypes (DENV-1, DENV-2, DENV-3, and DENV-4)2. These mosquitoes belong to the family Flaviviridae. They bite during the day. As per WHO reports,…
May 16, 2022

Read more

Exclusive_Anita Holz1_Alanna Morris2-2022
EXCLUSIVE

Exclusive Interview with PharmaShots: Anita Holz of Boehringer Ingelheim And Alanna Morris of Emory University Share Insight on Hear Your Heart

In an interview with PharmaShots, Anita Holz, MSN, CRNP, Therapeutic Area Head, Cardiometabolism Medical Affairs, Boehringer Ingelheim & Alanna Morris, Associate Professor of Medicine, Division of Cardiology, Emory University School of Medicine shared their views on the launch of Hear Your Heart to provide resources and education for women with heart failure & highlight inequitable care in black and Latina women Shots: Boehringer &…
May 16, 2022

Read more

PharmaShots Interview GSK’ Angela Carroll Shares Insights on First Paper to Define Disease Modification in Systemic Lupus Erythematosus
VIEWPOINTS

PharmaShots Interview: GSK’ Angela Carroll Shares Insights on First Paper to Define Disease Modification in Systemic Lupus Erythematosus

In an interview with PharmaShots, Angela Carroll, US Medical Affairs Scientific Director-Immuno-inflammation at GSK shared her views on a first published article on disease modification in systemic lupus erythematosus, published in Lupus Science & Medicine Shots: The company has published the first research to define disease modification in SLE including LN in the Lupus Science & Medicine. In multiple therapeutic…
May 11, 2022

Read more

PharmaShots Interview Biogen’s Toby Ferguson Shares Insights on the use of Spinraza for the Treatment of Spinal Muscular Atrophy
VIEWPOINTS

PharmaShots Interview: Biogen’s Toby Ferguson Shares Insights on the use of Spinraza for the Treatment of Spinal Muscular Atrophy

In an interview with PharmaShots, Toby Ferguson, Vice President & Head of the Neuromuscular Development Unit at Biogen shared his views on new data on Spinraza and improves clinical outcomes for the treatment of SMA patients Shots: The first patient has been treated in the P-IIIb (ASCEND) study evaluating the higher dose of nusinersen in 135 children, teens & adults with…
May 10, 2022

Read more

Exclusive_Todd Zavodnick_2022
EXCLUSIVE

Exclusive Interview with PharmaShots: Todd Zavodnick of Dermavant Shares Insight on the Appointment of Nancy Beesley with 25+ Years of Experience

In an interview with PharmaShots, Todd Zavodnick, CEO at Dermavant, shared his views on the addition of Nancy Beesley to its Board of Directors. She brings over 25 years of experience in commercializing and branding therapeutics for the treatment of various dermatological, ophthalmic, and neurological conditions and rare diseases Shots: The addition of Nancy as a board member…
May 9, 2022

Read more

Insights+ Key Biosimilars Events of April 2022
INSIGHTS+

Insights+ Key Biosimilars Events of April 2022

Biosimilars are developed to be highly similar versions of approved biologics in terms of safety, purity, and potency Biosimilars are expected to be a cost-effective alternative to the high-priced branded biologics, offering significant and much-needed cost savings to both payers and the patients During the month of April, Alvotech resolved a European patent dispute with…
May 5, 2022

Read more

PharmaShots Interview GSK’s Tom Corbridge Shares Insights on Nucala as At-Home Treatment Option for Children with Severe Eosinophilic Asthma
VIEWPOINTS

PharmaShots Interview: GSK’s Tom Corbridge Shares Insights on Nucala as At-Home Treatment Option for Children with Severe Eosinophilic Asthma

In an interview with PharmaShots, Tom Corbridge, Senior Medical Lead at GSK shared his views on the approval of its anti-IL-5 biologic NUCALA (mepolizumab) in a 40 mg pre-filled syringe for appropriate children aged 6 to 11 years old with severe eosinophilic asthma (SEA) Shots: Nucala can now be given by a child’s HCPs or administered…
May 4, 2022

Read more

PharmaShots Interview X4 Pharmaceuticals’ Paula Ragan Shares Insights on Mavorixafor for the Treatment of Multiple Immunodeficiencies
VIEWPOINTS

PharmaShots Interview: X4 Pharmaceuticals’ Paula Ragan Shares Insights on Mavorixafor for the Treatment of Multiple Immunodeficiencies

In an interview with PharmaShots, Paula Ragan, Ph.D., CEO, and President at X4 Pharmaceuticals shared her views on the data of Mavorixafor which showed increased immune cell levels regardless of patients having a CXCR4 mutation to treat multiple immunodeficiencies, presented at ASH 2021 Shots: The ongoing long-term extension arm of the P-II trial evaluates Mavorixafor (CXCR4 antagonist) in patients with WHIM syndrome. The therapy continues…
May 3, 2022

Read more

PharmaShots Interview Janssen’s Mark Wildgust Shares Insights on Imbruvica for Chronic Lymphocytic Leukemia and Darzalex for Multiple Myeloma
VIEWPOINTS

PharmaShots Interview: Janssen’s Mark Wildgust Shares Insights on Imbruvica for Chronic Lymphocytic Leukemia and Darzalex for Multiple Myeloma

In an interview with PharmaShots, Mark Wildgust, Vice President, Global Medical Affairs, Oncology at Janssen shared his views on the data of Imbruvica in P-III (GLOW) and P-II (CAPTIVATE) studies for the treatment of CLL or SLL and also highlighted the results of Darzalex in the P-II (GRIFFIN) & P-III (MAIA) study for multiple myeloma The P-III (GLOW) and P-II (CAPTIVATE) studies evaluating Imbruvica + venetoclax (I+V) as a…
May 2, 2022

Read more

Top Performing Drug of 2021 - Humira (April Edition)
INSIGHTS+

Top Performing Drug of 2021 – Humira (April Edition)

Active Ingredients: Adalimumab Strength: 40 mg/0.8 ml Dosage Form: Syringe, Vial Mechanism of Action: TNF-alpha inhibitors First Approval: US (Dec 31, 2002), EU (Aug 09, 2003) Revenue Humira (adalimumab) has been the top-selling biologic drug product for the last few years – reaching nearly $21B in annual sales in 2021. Humira is one of the main drivers of AbbVie’s immunology…
April 29, 2022

Read more

Load more